Oscar HealthOSCR
Recorded

Oscar Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration50 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you, everyone. Good morning. My name is Erica, and I will be your conference operator. At this time, I would like to welcome everyone to Oscar Health's third quarter 2026 earnings conference call. I will now turn the call over to Chris Potochar, Vice President of Treasury and Investor Relations.

Chris PotocharVP of Treasury and Investor Relations

Please go ahead. Good morning, everyone.

Chris PotocharVP of Treasury and Investor Relations

Thank you for joining us for our third quarter 2026 earnings call. Mark Bertolini, Oscar Health's Chief Executive Officer, and Scott Blackley, Oscar Health's Chief Financial Officer, will host this morning's call. This call can also be accessed through our investor relations website at ir.oscarhealth.com. Full details of our results and additional management commentary are available in our earnings release, which can be found on our investor relations website at ir.oscarhealth.com. Any remarks that Oscar makes about the future constitute forward-looking statements within the meaning of safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Chris PotocharVP of Treasury and Investor Relations

Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in our annual report on Form 10-K for the period ended December 31, 2025, and the quarterly report on Form 10-Q for the period ended June 30, 2026. Each is filed with the Securities and Exchange Commission and other filings with the SEC, including our quarterly report on Form 10-Q for the period ended September 30, 2026, to be filed with the SEC. Such forward-looking statements are based on current expectations as of today. Oscar anticipates that subsequent events and developments may cause estimates to change. While the company may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. The call will also refer to certain non-GAAP measures.

Chris PotocharVP of Treasury and Investor Relations

A reconciliation of these measures to the most directly comparable GAAP measures can be found in the third quarter earnings press release available on the company's investor relations website at ir.oscarhealth.com. We have not provided a quantitative reconciliation of estimated full-year 2026 Adjusted EBITDA as described in this call to GAAP net income because Oscar is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. With that, I will turn the call over to our CEO, Mark Bertolini.

Mark BertoliniCEO

Good morning. Thank you, Chris, and thank you all for joining us. 2026 is the strongest year in Oscar Health's history. We delivered record profitability for the first nine months of the year, reporting earnings from operations of $1.3 billion and net income of $1.2 billion. We also expect to achieve several of our 2024 Investor Day commitments one year ahead of plan. Based on our performance year to date, we are raising 2026 earnings from operations guidance for a third time to a range of $850 million-$950 million. Our strong third quarter performance exceeded our expectations with improvement across all core metrics. Revenue grew roughly 70% year-over-year to $5.1 million. Our SG&A expense ratio improved 350 basis points year-over-year to 14%, another record low reflecting the disciplined execution, greater fixed cost leverage, and AI-driven efficiencies.

Mark BertoliniCEO

MLR improved 450 basis points over the prior year period to 84%. Earnings from operations increased $307 million year-over-year to $178 million, and Adjusted EBITDA increased $308 million to $207 million. Before I turn to our business highlights, I will share our perspective on current market trends. The ACA is the foundation of a rapidly developing individual market. Americans are building careers on their own terms. They are starting businesses, combining part-time work, participating in the gig economy, and retiring early. More than 19 million people rely on the ACA, yet 28 million American workers remain uninsured. Affordable coverage gives people greater financial security to pursue new opportunities and helps employers build a more stable workforce. Both parties understand healthcare is a priority for the American people.

Mark BertoliniCEO

We have a significant opportunity to expand the ACA into a competitive marketplace that improves affordability and supports a resilient economy. Our 2026 performance demonstrates the strength of our operating model. We remain focused on growing market share and expanding margin in 2027. Our weighted average rate increase of approximately 14% for 2027 open enrollment period reflects elevated trend and higher market morbidity. Pricing is one lever of our growth model. We also target markets where our products and distribution network address consumer needs, including opportunities created by competitor exits. These strengths, combined with our medical cost management, operating efficiency, and superior technology, will drive sustainable financial performance in 2027 and beyond. Now I will review our business highlights. Oscar Insurance ended the third quarter with 2.7 million members, up 27% year-over-year. We are entering open enrollment with a 24% larger footprint, spanning 713 counties.

Mark BertoliniCEO

We are also expanding into South Carolina. Our expansion increases our total addressable market to approximately 10 million consumers across 21 states. Oscar is launching a new wave of consumer lifestyle products. Our newest product, RetireEase, is live in select markets and serves a growing segment of 2.5 million early retirees in the ACA. Members keep their trusted doctors and receive set prices for preventative services, physical therapy, and heart, bone, and joint care. We are also addressing affordability through bundled benefits. Hundreds of Oscar plans now include dental and vision coverage. In addition, our new Allstate Health Solutions partnership pairs Oscar plans with low-cost supplemental coverage to help bronze members manage out-of-pocket costs. Each product meets a distinct consumer need and extends our reach into high-value, underserved segments. Our Oscar team is also scaling CHOICE.

Mark BertoliniCEO

Our Hy-Vee Health with Oscar product is expanding from Iowa into Nebraska, Missouri, and Kansas. This product's concierge care model earns a 92% satisfaction rate and can now serve more small businesses, part-time employees, and gig workers. We are also launching HelloMeno off-exchange to better serve women across the workforce. Employer demand is building. CHOICE adoption is growing fastest in healthcare, technology, construction, and manufacturing sectors across Oscar states. Oscar's health technology puts consumers in control of their healthcare decisions across two platforms. The Oscar platform now includes new AI capabilities that make our product suite easy to understand. The Lucie platform serves the broader market, personalizing the healthcare shopping experience at scale. Lucie instantly matches consumers with plans from major ACA carriers and select supplemental carriers, and guides brokers through CMS eligibility. No other platform brings these capabilities together in one place.

Mark BertoliniCEO

Lucie is on track to sell approximately 800,000 new policies in 2027, driven by growing broker and consumer demand. Oscar Health's third quarter performance puts us on track to deliver strong results one year ahead of plan. Our disciplined pricing, product innovation, and technology-powered support are delivering superior member experiences and efficiency across the company. The individual market opportunity is growing. People expect healthcare to work like the best consumer products: simple, transparent, and personalized. We are building a consumer healthcare company that meets those expectations and serves a much larger market. The team is positioned to grow market share and expand margin in 2027. We are also on track to deliver our long-term targets, including at least $4 earnings per share by 2029. Thank you to the Oscar Health team for giving people power over their healthcare. With that, I will turn the call over to Scott.

Scott BlackleyCFO

Scott? Thank you, Mark, and good morning, everyone.

Scott BlackleyCFO

Sorry for the voice. I am recovering from a cold today. Through the first nine months of 2026, we delivered net income of approximately $1.2 billion, or $3.59 per diluted share. Earnings from operations were approximately $1.3 billion. Based on these strong results and underlying trends, we are raising our full-year 2026 outlook. Turning now to third quarter results. We ended the quarter with approximately 2.7 million members, an increase of 27% year-over-year. Sequential decline in membership primarily reflects dis-enrollments from CMS's industry-wide eligibility review, which was in line with expectations. From a second smaller CMS review, we expect a small number of additional dis-enrollments in the fourth quarter. Total revenue increased approximately 70% year-over-year to $5.1 billion, driven by rate increases and higher membership. During the quarter, we received updated risk adjustment data.

Scott BlackleyCFO

We saw significant improvement in Oscar's risk relative to the market, and market morbidity was modestly favorable to our expectations. These factors drove a $250 million revenue benefit in the quarter. Risk adjustment as a percentage of premiums was 11.8% in the third quarter and 17.2% through the first nine months. While the additional data gives us greater visibility and more confidence in our risk adjustment accruals, we continue to take a cautious approach to our risk adjustment reserves. The third quarter medical loss ratio was 84%, an improvement of 450 basis points year-over-year. Improvement was primarily driven by our disciplined pricing strategy. Overall, year-to-date utilization was moderately favorable to our expectations. By category, inpatient, professional, and pharmacy utilization were favorable, while outpatient was elevated. We believe some of the elevated outpatient utilization reflects a rotation from inpatient to outpatient care, driven in part by our affordability initiatives.

Scott BlackleyCFO

Switching to administrative costs. The third quarter SG&A expense ratio was 14%, the lowest in the company's history. The approximately 350 basis point year-over-year improvement was driven by lower risk adjustment as a percentage of premium, higher fixed cost leverage, and disciplined expense management, including an increasing impact from technology and AI initiatives. We reported earnings from operations of $178 million in the third quarter, a $307 million year-over-year improvement. Operating margin was 3.5%, an improvement of approximately 780 basis points year-over-year. Net income was $167 million, a $305 million increase year-over-year. Adjusted EBITDA was $207 million in the quarter, an increase of $308 million year-over-year. Shifting to the balance sheet. We ended the third quarter with approximately $9 billion of cash and investments, including $360 million of cash and investments at the parent.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day